Drug Resistance Patterns in Mycobacterium Tuberculosis
Summary
Mycobacterium tuberculosis (M. tuberculosis) drug resistance poses a critical challenge to global tuberculosis control, driven by both genetic mutation and selective pressure from antimicrobial therapy. Resistance arises when spontaneous mutations in target genes, notably rpoB (rifampicin resistance) and katG or inhA (isoniazid resistance), confer survival advantage under drug exposure. Multidrug-resistant tuberculosis (MDR-TB) resists at least isoniazid and rifampicin, while extensively drug-resistant TB (XDR-TB) exhibits additional resistance to fluoroquinolones and second-line injectable agents. The predominance of certain lineages, especially the Beijing genotype, is associated with higher transmission and resistance rates. Surveillance through phenotypic drug-susceptibility testing and molecular methods such as whole-genome sequencing and MIRU-VNTR typing has revealed heterogeneous resistance patterns across regions, influenced by treatment history, healthcare infrastructure and social determinants. Rapid molecular diagnostics enable earlier detection of resistance and tailored therapy, but the emergence of mono-resistance, combined resistance and compensatory mutations, underlines the need for novel drugs, strengthened treatment adherence, and integrated public-health interventions to curb dissemination.
Research from Nature Portfolio
Analysis of multidrug-resistant isolates from a high-burden region in China revealed that over 80% belonged to the Beijing lineage, highlighting its role in MDR-TB propagation. Sequencing of rpoB, katG, inhA promoter and ahpC regions in phenotypically confirmed MDR strains demonstrated mutation frequencies exceeding 85% in core resistance loci, with Ser531Leu in rpoB and Ser315Thr in katG most prevalent. MIRU-VNTR genotyping indicated substantial genetic diversity within clusters, suggesting both recent transmission and independent emergence of resistance. These findings underscore the value of integrating genotypic characterisation with traditional susceptibility testing to inform surveillance and guide regimen optimisation in areas where first-line drug resistance remains high.
Drug Resistance Patterns in Mycobacterium Tuberculosis publication trend
The graph below shows the total number of articles in drug resistance patterns in mycobacterium tuberculosis across all publications each year (not limited to Nature Index journals).
Technical terms
Multidrug-resistant tuberculosis (MDR-TB): Disease caused by M. tuberculosis resistant to at least isoniazid and rifampicin, the two most potent first-line drugs.
Extensively drug-resistant tuberculosis (XDR-TB): MDR-TB with additional resistance to any fluoroquinolone and at least one second-line injectable agent.
Whole-genome sequencing (WGS): High-throughput method that determines the complete DNA sequence of an organism’s genome, enabling comprehensive detection of resistance-conferring mutations.
MIRU-VNTR typing: Molecular fingerprinting technique analysing variable-number tandem repeats at multiple mycobacterial interspersed repetitive units to assess strain diversity and transmission dynamics.
rpoB gene: Encodes the β subunit of RNA polymerase; mutations in an 81-base-pair core region confer rifampicin resistance.
References
- Transmission of multidrug-resistant tuberculosis in Jiangxi, China, and associated risk factors. Microbiology Spectrum (2024).
- The mutation rate of rpoB gene showed an upward trend with the increase of MIRU10, MIRU39 and QUB4156 repetitive number. BMC Genomics (2023).
- Drug Resistance Characteristics of Mycobacterium tuberculosis Isolates From Patients With Tuberculosis to 12 Antituberculous Drugs in China. Frontiers in Cellular and Infection Microbiology (2019).
- Prevalence and molecular characterization of multidrug-resistant M. tuberculosis in Jiangxi province, China. Scientific Reports (2019).
About these summaries
This Nature Research Intelligence Topic summary is created with the cited references and a large language model. We take care to ground generated text with facts, and have systems in place to gain human feedback on the overall quality of the process in line with our AI principles. We strive to create accurate and useful summaries for people unfamiliar with the research topic and that supports this goal. These pages are a beta release and will be updated as we learn how best to help people gain value from a research topic summary.
Turn complex research questions into confident strategic decisions
When you're under pressure to set direction, justify investment, or understand your competitive position, you need more than raw data — you need trusted insights you can act on.
Benchmark your performance against global peers using robust, methodologically sound analysis.
Combine quantitative metrics with qualitative expert insight to uncover strengths, gaps and emerging opportunities.
Gain tailored, decision-ready recommendations aligned to your strategic priorities.
Talk to us to learn more about our data dashboards and bespoke strategy reports.
Grow research skills, confidence and careers with training built for every stage of the research lifecycle.
Developed with Nature Portfolio journal Editors and internationally renowned experts. Discover three ways to learn:
Self-paced, online courses in convenient bite-sized units, covering key skills across scientific writing, publishing, grant writing, data analysis, and more.
Expert trainer-led workshops with hands-on exercises and real-time feedback across core research skills, delivered via interactive group sessions.
Editor-led workshops combining core principles in writing and publishing, personalised 1:1 feedback from Nature Portfolio Editors and hands-on exercises.
Explore course catalogues and workshop agendas, enquire about the options or request institutional pricing.